Survival outcomes from atezolizumab plus bevacizumab versus Lenvatinib in Child Pugh B unresectable hepatocellular carcinoma patients

被引：0

作者：

Margherita Rimini

Mara Persano

Toshifumi Tada

Goki Suda

Shigeo Shimose

Masatoshi Kudo

Jaekyung Cheon

Fabian Finkelmeier

Ho Yeong Lim

José Presa

Francesca Salani

Sara Lonardi

Fabio Piscaglia

Takashi Kumada

Naoya Sakamoto

Hideki Iwamoto

Tomoko Aoki

Hong Jae Chon

Vera Himmelsbach

Marta Schirripa

Margarida Montes

Caterina Vivaldi

Caterina Soldà

Atsushi Hiraoka

Takuya Sho

Takashi Niizeki

Naoshi Nishida

Christoph Steup

Masashi Hirooka

Kazuya Kariyama

Joji Tani

Masanori Atsukawa

Koichi Takaguchi

Ei Itobayashi

Shinya Fukunishi

Kunihiko Tsuji

Toru Ishikawa

Kazuto Tajiri

Hironori Ochi

Satoshi Yasuda

Hidenori Toyoda

Chikara Ogawa

Takashi Nishimura

Takeshi Hatanaka

Satoru Kakizaki

Noritomo Shimada

Kazuhito Kawata

Fujimasa Tada

Hideko Ohama

Kazuhiro Nouso

机构：

[1] Vita-Salute San Raffaele University,Department of Oncology

[2] IRCCS San Raffaele Scientific Institute Hospital,Department of Oncology

[3] IRCCS San Raffaele Hospital,Medical Oncology

[4] University and University Hospital of Cagliari,Department of Internal Medicine

[5] Japanese Red Cross Himeji Hospital,Department of Gastroenterology and Hepatology, Graduate School of Medicine

[6] Hokkaido University,Division of Gastroenterology, Department of Medicine

[7] Kurume University School of Medicine,Department of Gastroenterology and Hepatology, Faculty of Medicine

[8] Kindai University,Department of Medical Oncology

[9] CHA Bundang Medical Center,Department of Internal Medicine 1

[10] CHA University School of Medicine,Department of Medicine, School of Medicine

[11] University Hospital Frankfurt,Unit of Medical Oncology 2

[12] Goethe University,Department of Translational Research and New Technologies in Medicine and Surgery

[13] Samsung Medical Center,Oncology Unit 1

[14] Sungkyunkwan University,Division of Internal Medicine, Hepatobiliary and Immunoallergic Diseases

[15] Unidade de Hepatologia,Department of Nursing

[16] CHTMAD,Medical Oncology Unit, Department of Oncology and Hematology

[17] University Hospital of Pisa,Gastroenterology Center

[18] University of Pisa,Department of Gastroenterology and Metabology

[19] Veneto Institute of Oncology IOV-IRCCS,Department of Gastroenterology

[20] IRCCS Azienda Ospedaliero-Universitaria di Bologna,Department of Gastroenterology and Hepatology

[21] Gifu Kyoritsu University,Department of Hepatology

[22] Central Hospital of Belcolle,Department of Gastroenterology

[23] Strada Sammartinese Snc,Department of Gastroenterology

[24] Ehime Prefectural Central Hospital,Center of Gastroenterology

[25] Ehime University Graduate School of Medicine,Department of Gastroenterology

[26] Okayama City Hospital,Department of Gastroenterology

[27] Kagawa University,Hepato

[28] Division of Gastroenterology and Hepatology,Biliary Center

[29] Department of Internal Medicine,Department of Gastroenterology and Hepatology

[30] Nippon Medical School,Department of Gastroenterology

[31] Kagawa Prefectural Central Hospital,Department of Internal Medicine, Division of Gastroenterology and Hepatology

[32] Asahi General Hospital,Department of Gastroenterology

[33] Osaka Medical and Pharmaceutical University,Department of Clinical Research

[34] Teine Keijinkai Hospital,Division of Gastroenterology and Hepatology

[35] Saiseikai Niigata Hospital,Department of Hepatology

[36] Toyama University Hospital,Department of Surgery

[37] Japanese Red Cross Matsuyama Hospital,Department of Gastroenterology

[38] Ogaki Municipal Hospital,Department of Biomedical Sciences

[39] Japanese Red Cross Takamatsu Hospital,undefined

[40] Hyogo Medical University,undefined

[41] Gunma Saiseikai Maebashi Hospital,undefined

[42] National Hospital Organization Takasaki General Medical Center,undefined

[43] Otakanomori Hospital,undefined

[44] Hamamatsu University School of Medicine,undefined

[45] Kansai Medical University,undefined

[46] National Hospital Organization Takasaki General Medical Center,undefined

[47] Humanitas University,undefined

来源：

Journal of Cancer Research and Clinical Oncology | 2023年 / 149卷

关键词：

Advanced HCC; Atezolizumab; Bevacizumab; Real Word;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：7565 / 7577

页数：12

共 50 条

[41] Lenvatinib plus checkpoint inhibitors (ICIs) versus sorafenib plus ICIs as first-line treatment for unresectable hepatocellular carcinoma with Child-Pugh B
Ding, X.
Chen, J.
[J]. ANNALS OF ONCOLOGY, 2023, 34 : S131 - S132
[42] Transarterial Chemoembolization Combined with Atezolizumab Plus Bevacizumab or Lenvatinib for Unresectable Hepatocellular Carcinoma: A Propensity Score Matched Study
Zhao, Chenghao
Xiang, Zhanwang
Li, Mingan
Wang, Haofan
Liu, Huan
Yan, Huzheng
Huang, Mingsheng
[J]. JOURNAL OF HEPATOCELLULAR CARCINOMA, 2023, 10 : 1195 - 1206
[43] Is Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma Superior Even to Lenvatinib? A Matching-Adjusted Indirect Comparison
Andrea Casadei-Gardini
Toshifumi Tada
Shigeo Shimose
Takashi Kumada
Takashi Niizeki
Stefano Cascinu
Alessandro Cucchetti
[J]. Targeted Oncology, 2021, 16 : 249 - 254
[44] Is Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma Superior Even to Lenvatinib? A Matching-Adjusted Indirect Comparison
Casadei-Gardini, Andrea
Tada, Toshifumi
Shimose, Shigeo
Kumada, Takashi
Niizeki, Takashi
Cascinu, Stefano
Cucchetti, Alessandro
[J]. TARGETED ONCOLOGY, 2021, 16 (02) : 249 - 254
[45] Atezolizumab plus bevacizumab versus lenvatinib or sorafenib in non-viral unresectable hepatocellular carcinoma: an international propensity score matching analysis
Rimini, M.
Rimassa, L.
Ueshima, K.
Burgio, V
Shigeo, S.
Tada, T.
Suda, G.
Yoo, C.
Cheon, J.
Pinato, D. J.
Lonardi, S.
Scartozzi, M.
Iavarone, M.
Di Costanzo, G. G.
Marra, F.
Solda, C.
Tamburini, E.
Piscaglia, F.
Masi, G.
Cabibbo, G.
Foschi, F. G.
Silletta, M.
Pressiani, T.
Nishida, N.
Iwamoto, H.
Sakamoto, N.
Ryoo, B-Y
Chon, H. J.
Claudia, F.
Niizeki, T.
Sho, T.
Kang, B.
D'Alessio, A.
Kumada, T.
Hiraoka, A.
Hirooka, M.
Kariyama, K.
Tani, J.
Atsukawa, M.
Takaguchi, K.
Itobayashi, E.
Fukunishi, S.
Tsuji, K.
Ishikawa, T.
Tajiri, K.
Ochi, H.
Yasuda, S.
Toyoda, H.
Ogawa, C.
Nishimur, T.
[J]. ESMO OPEN, 2022, 7 (06)
[46] Therapeutic efficacy of atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma in patients with Child-Pugh class A or B liver function in real-world clinical practice
Tanaka, Takaaki
Hiraoka, Atsushi
Tada, Toshifumi
Hirooka, Masashi
Kariyama, Kazuya
Tani, Joji
Atsukawa, Masanori
Takaguchi, Koichi
Itobayashi, Ei
Fukunishi, Shinya
Tsuji, Kunihiko
Ishikawa, Toru
Tajiri, Kazuto
Ochi, Hironori
Yasuda, Satoshi
Toyoda, Hidenori
Ogawa, Chikara
Nishimura, Takashi
Hatanaka, Takeshi
Kakizaki, Satoru
Shimada, Noritomo
Kawata, Kazuhito
Naganuma, Atsushi
Kosaka, Hisashi
Ohama, Hideko
Nouso, Kazuhiro
Morishita, Asahiro
Tsutsui, Akemi
Nagano, Takuya
Itokawa, Norio
Okubo, Tomomi
Arai, Taeang
Imai, Michitaka
Koizumi, Yohei
Nakamura, Shinichiro
Joko, Kouji
Iijima, Hiroko
Kaibori, Masaki
Hiasa, Yoichi
Kudo, Masatoshi
Kumada, Takashi
[J]. HEPATOLOGY RESEARCH, 2022, 52 (09) : 773 - 783
[47] Clinical Outcomes With Lenvatinib in Patients Previously Treated With Atezolizumab/Bevacizumab for Advanced Hepatocellular Carcinoma
Muto, Hisanori
Kuzuya, Teiji
Kawabe, Naoto
Ohno, Eizaburo
Funasaka, Kohei
Nagasaka, Mitsuo
Nakagawa, Yoshihito
Miyahara, Ryoji
Shibata, Tomoyuki
Hashimoto, Senju
Katano, Yoshiaki
Hirooka, Yoshiki
[J]. ANTICANCER RESEARCH, 2023, 43 (10) : 4673 - 4682
[48] Efficacy and safety of atezolizumab plus bevacizumab in patients with portal hypertension for unresectable hepatocellular carcinoma
Kinami, Takahiro
Uchikawa, Shinsuke
Kawaoka, Tomokazu
Yamasaki, Shintaro
Kosaka, Masanari
Johira, Yusuke
Yano, Shigeki
Amioka, Kei
Naruto, Kensuke
Yamaoka, Kenji
Fujii, Yasutoshi
Fujino, Hatsue
Nakahara, Takashi
Ono, Atsushi
Murakami, Eisuke
Okamoto, Wataru
Yamauchi, Masami
Miki, Daiki
Tsuge, Masataka
Oka, Shiro
[J]. CANCER MEDICINE, 2024, 13 (05):
[49] Bayesian Analysis Supports Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma
Rizzo, Alessandro
Ricci, Angela Dalia
Brandi, Giovanni
[J]. LIVER CANCER, 2022, 11 (02) : 180 - 181
[50] Hyperprogressive disease in patients with unresectable hepatocellular carcinoma receiving atezolizumab plus bevacizumab therapy
Maesaka, Kazuki
Sakamori, Ryotaro
Yamada, Ryoko
Tahata, Yuki
Imai, Yasuharu
Ohkawa, Kazuyoshi
Miyazaki, Masanori
Mita, Eiji
Ito, Toshifumi
Hagiwara, Hideki
Yakushijin, Takayuki
Kodama, Takahiro
Hikita, Hayato
Tatsumi, Tomohide
Takehara, Tetsuo
[J]. HEPATOLOGY RESEARCH, 2022, 52 (03) : 298 - 307

← 1 2 3 4 5 →